Neuronix’s NeuroAD Treatment Can Reverse Alzheimer’s Symptoms to a State Comparable to Two Years before Treatment
Successful results from a clinical trial at Harvard are offering new hope for millions of Alzheimer’s patients and their families around the world. The trial, conducted at the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center (Boston, MA), a teaching hospital of Harvard Medical School, tested the NeuroAD Medical Device: a non-invasive, novel technology which combines electromagnetic stimulation of the brain concurrently with cognitive training. Both the stimulation and the training are simultaneously targeted at specific brain regions affected by the disease.
The interim findings have been remarkable and coincide with results from previous clinical trials conducted in Israel. The NeuroAD system not only stopped patients from deteriorating, it actually improved patients’ cognitive performance to a greater extent than what is currently available with approved medications.
The trial was directed by Professor of Neurology, Alvaro Pascual-Leone of Harvard Medical School. “It is a completely new and different approach, safe, noninvasive, and painless,” said Prof. Pascual-Leone. “Tests have shown significant improvement of cognitive functions, and we’ve seen increased connectivity in the brain in functional MRI scans. As a result, patients’ daily activities such as taking care of themselves, speaking, and even recognizing their loved ones have improved dramatically.”
“This far exceeds what is currently available with medications today,” added Pascual-Leone. “New ideas for treatment which show such promise are very rare indeed, so we are very optimistic.”
“Wherever we go, physicians are eager to hear about this new technology because nothing else is available to help patients,” said Eyal Baror, CEO of Israel-based Neuronix, the company behind the NeuroAD technology. “NeuroAD is CE certified and we are aiming at FDA approval. It is a real game-changer for the management of Alzheimer’s disease; hence we plan to start two more clinical trials in the U.S. before the end of this year.”
Currently, there is no cure for Alzheimer’s disease. Though there are drugs that can relieve some of the symptoms, the benefit usually diminishes within 6-9 months of treatment. NeuroAD, which can be used in conjunction with these therapies, has shown more significant impact as well as long-term results.
5.4 million Americans and an estimated 35 million people globally suffer from Alzheimer’s disease, and the number is expected to triple in one generation. The estimated annual cost of the disease to the U.S. economy alone is $200 billion.
That is why the Obama Administration and the NIH recently initiated a major effort to combat Alzheimer’s disease, aiming at effective treatment by 2025.
NeuroAD is an investigational device, currently not available in the USA
About Neuronix Medical
Founded in 2008, Neuronix Medical’s mission is to find a method for modifying the course of treatment of Alzheimer’s disease (AD), and thus provide long-term improvement in the quality of life for patients. Led by a highly motivated management team and supported by key opinion leaders in the field, Neuronix holds all the basic elements for becoming a leading medical device company, and fulfilling its vision to provide relief for millions of AD patients worldwide. The company’s solution, NeuroAD™, is based on a novel, patent pending technology, using stimulation of affected brain regions concurrently interlaced with cognitive training, directed at specific brain regions affected by the disease. The stimulation induces LTP (Long Term Potentiation), which is associated with learning and memory processes, and results in a measurable cognitive improvement after just a few weeks of treatment. For more information, visit www.neuronixmedical.com.
The mission of the Beth Israel Deaconess Medical Center (www.bidmc.org) is to serve our patients compassionately and effectively, and to create a healthy future for them and their families. BIDMC’s mission is supported by our commitment to personalized, excellent care for our patients; a workforce committed to individual accountability, mutual respect and collaboration; and a commitment to maintaining our financial health. Critical to our success is the partnership between the medical center and its physicians. It is this partnership that allows the medical center to carry out its mission of teaching, research and clinical care. BIDMC’s partnership with Harvard Medical School and its role as a major Harvard teaching hospital strengthen its ability to train, teach and create new knowledge. BIDMC’s is committed to recruiting the best physicians, scientists, nurses and others to support these activities.
July 16, 2012. Neuronix Ltd., Yoqneam, Israel